Published: Tuesday, October 29, 2024 · 9:41 PM | Updated: Tuesday, October 29, 2024 · 9:41 PM
📊 481 views
🗝️ Key Points
- On October 29, 2024, AtriCure Inc (ATRC, Financial) released its 8-K filing detailing the financial results for the third quarter of 2024.
- AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, reported a worldwide.
- This represents a 17.9% increase year-over-year, driven by strong adoption of its innovative medical devices.Company Overview and Market Position AtriCure Inc is renowned for.
On October 29, 2024, AtriCure Inc (ATRC, Financial) released its 8-K filing detailing the financial results for the third quarter of 2024. AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, reported a worldwide revenue of $115.9 million, exceeding the analyst estimate of $112.25 million. This represents a 17.9% increase year-over-year, driven by strong adoption of its innovative medical devices.
Company Overview and Market Position
AtriCure Inc is renowned for its innovative solutions in the medical devices and instruments industry, particularly focusing on Afib and LAA management. The company markets its products primarily in the United States, with a significant portion of its revenue generated domestically. Its Product offerings include Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and minimally invasive ablation devices, which cater to the growing demand for less invasive cardiac and thoracic surgeries.
Financial Performance and Key Metrics
The third quarter of 2024 saw AtriCure achieving a U.S. revenue of $95.5 million, marking a 16.8% increase from the previous year. International revenue also showed robust growth, increasing by 23.3% to $20.5 million. The company’s gross profit rose to $86.8 million, with a gross margin of 74.9%, slightly down by 27 basis points due to geographic and product mix variations.
Despite a loss from operations of $7.4 million, AtriCure reported a basic and diluted net loss per share of $0.17, which is an improvement from the $0.20 loss per share in the same quarter last year. The adjusted EBITDA for the quarter was $7.9 million, up by $3.2 million year-over-year, indicating enhanced operational efficiency.
Strategic Initiatives and Market Expansion
AtriCure’s strategic initiatives, including the launch of new products in the U.S. and Europe, have contributed to its accelerated growth and improved profitability. The company’s focus on expanding access to its solutions has been pivotal in driving revenue growth across its key product lines, such as the ENCOMPASS® clamp and AtriClip® Flex·V® device.
“Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business,” said Michael Carrel, President and Chief Executive Officer at AtriCure.
Financial Outlook and Industry Implications
Looking ahead, AtriCure has revised its full-year 2024 revenue guidance to approximately $459 million to $462 million, reflecting a growth rate of 15% to 16%. The company also anticipates an adjusted EBITDA of $26 million to $29 million for the year, representing a significant increase from 2023. This positive outlook underscores AtriCure’s strong market position and its ability to capitalize on the growing demand for innovative medical solutions.
In summary, AtriCure Inc’s third-quarter results highlight its successful execution of strategic initiatives and its robust financial performance, making it a noteworthy player in the medical devices and instruments industry. The company’s ability to exceed revenue expectations and generate positive cash flow positions it well for continued growth and value creation for its stakeholders.
Explore the complete 8-K earnings release (here) from AtriCure Inc for further details.
MORE IN INSIDE INVESTMENT NEWS
Marvell stock surges 20% as CEO points to continuing AI demand: ‘Do you see me blinking?’
Published: Friday, March 6, 2026 · 6:17 PM
Marvell stock surges 18% as CEO points to continuing AI demand: ‘Do you see me blinking?’
Published: Friday, March 6, 2026 · 4:40 PM
